# CBAT earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/CBAT) · [Earnings tab](https://www.lopjlb.com/stock/CBAT?tab=earnings) Updated: 2026-08-17T10:38:16 Quarters analyzed: 8 ## Cross-quarter narrative Across the series of CallCards, CBAT moved from a period of strong revenue growth and record battery gross margins in late 2023 to a phase marked by margin compression, revenue volatility and execution challenges. The battery segment’s gross margin peaked at 36% in 2023 Q4 and briefly rose to 41.2% in 2024 Q1, then slipped to the low‑30s by 2024 Q4 and fell to 7.3% in 2025 Q4 as new 40135 lines ramped. Demand remained robust, with a consistently large order backlog anchored by Viessmann, Anker and PowerOAK, yet visibility weakened during the Dalian transition and Southeast‑Asia expansion. Capacity expansion programmes—Nanjing Phase 2, Dalian 40135 and overseas factories—experienced repeated delays, equipment‑supply pricing concerns and relocation risks, pushing full‑scale output into 2026‑2027. Hitrans, once a drag, showed a turnaround with revenue up 59% in 2025 Q2 and profit improvement in 2025 Q3. Geopolitical and tariff uncertainties persisted, prompting customers to seek offshore production and creating policy‑risk exposure. Overall, the narrative shifts from rapid growth and high margins to a restructuring phase where margin pressure, execution risk and external policy factors dominate the outlook. ## Latest CallCard · Q4 CBAK Energy posted Q4 2025 revenue up 132% on new 40135 cell line, but margin compression from capacity ramps; expects margins to improve in H2 2026 as ramps finish. **Guidance:** raised — Management expressed absolute confidence that consolidated sales will hit a record high in 2026. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.5 CEO highlighted structural upgrade, aggressive capacity expansion and strong demand for new 40135 cells, projecting record sales in 2026. ### Demand visibility Demand for new 40135 cells exceeds supply, order book outpaces ramp‑up. Customers are transitioning to Model 40135; demand far exceeds available supply and the order book heavily outpaces current ramp‑up trajectory, with strong uptake in Africa, India and Southeast Asia. ### Margins / costs Gross margin fell to 7.3% Q4 due to ramp‑up costs and higher raw‑material prices. Q4 gross margin dropped from 13.1% to 7.3% as new Dalian and Nanjing lines incurred higher unit costs, suboptimal yields and fixed‑cost absorption; raw‑material price cycle also pressured margins. ### Capital allocation 2025 capex $44.65M funded new facilities and Malaysian plant. Allocated $44.65M to construct and equip new production lines at Dalian, Nanjing, Zhejiang and Anhui, and to build a manufacturing facility in Malaysia; cash and equivalents rose to $75.68M. ### Milestones - **40135 product line Dalian** [delivered]: Commissioned end 2025 with 2.3 GWh capacity. - **Phase II Nanjing lines** [on_track]: Two new lines adding 3.0 GWh; full capacity expected early 2027. - **Battery pack integration Nanjing BFD** [new]: Started 2025 to assemble cells into plug‑and‑play packs for African LEV swapping. - **SPIRO partnership** [delivered]: Strategic partnership forged 2025; SPIRO now a top‑5 customer. - **Hitrans cathode plant** [at_risk]: 10,000‑ton plant slated for first half 2027. - **Hitrans precursor facility** [new]: 37,000‑ton capacity under construction; timeline not disclosed. - **Malaysian subsidiary & plant** [on_track]: Incorporated April 30 2025; construction underway in 2025. - **Redomicile merger to Cayman Islands** [delivered]: Shareholders approved move to streamline operations and align with international expansion. ### Fears / risks - **Operational**: Capacity ramp‑up causing margin compression and higher unit costs. - **Macro**: Chinese export‑tax rebate reductions to 6% by Apr 2026 and elimination by Jan 2027 may pressure margins. - **Supply Chain**: Order book outpaces current production capacity for 40135 cells. - **Customer Concentration**: Reliance on top African customer SPIRO and other Tier‑1 clients for revenue growth. - **Regulatory**: Potential changes in export‑tax policy and local regulations affecting international margins. - **Financial**: Operating loss of $18.44 M despite strong cash flow; reliance on hedging to manage volatility. - **Legal**: Enforcement of $5 M compensation from a canceled order highlights contract‑risk exposure. - **R&D**: Development of large‑format cylindrical and sodium‑ion cells carries technical risk and timeline uncertainty. ### Key quotes > “The fiscal year 2025 was a definitive transitional period for CBAK Energy, characterized by our comprehensive structural upgrade of our product portfolio, aggressive capacity expansion and deliberate pivot toward next-generation form” > “Demand for the 40135 cells currently far exceeds our available supply. Meaning, we are selling every single unit we can produce, and our order book heavily outpace our current ramp-up trajectory.” > “Our gross profit for Q4 2025 was about $4.28 million, representing a gross margin of 7.3% compared to 13.1% in Q4 2024. This sharp margin compression was fundamentally driven by the transactional friction costs, suboptimal yields and” > “Ideally, in the second half of this year, our gross margin will gradually revolve. And I believe in the full year of 2026, the gross margin number at least looks better than right now.” > “Now I've reviewed the 40135 ramp-up data and the margin compression. And I have a structural and validated solution for the thermal wall and charging limitations impacting you daily in production.” — Unknown Analyst ## Quarter one-liners - **2025 Q4:** CBAK Energy posted Q4 2025 revenue up 132% on new 40135 cell line, but margin compression from capacity ramps; expects margins to improve in H2 2026 as ramps finish. - **2025 Q3:** CBAK Q3 revenue up 36.5% YoY to $50.9M driven by Hitrans raw material recovery (143.7% YoY) and stabilizing battery business; Nanjing Phase II and Dalian 40135 expansions on track for 2026 growth; overseas expansion pending China export policy clarity. - **2025 Q2:** CBAT Q2 revenue fell 15% YoY to $40.5M due to Dalian transition from 26650 to 40135 and Nanjing Phase 2 delay; management expects strong recovery by year-end as both projects complete; Hitrans revenue up 59%. - **2025 Q1:** CBAT Q1 revenue fell 41% YoY to $34.9M amid Dalian line upgrade to Model 40135; Nanjing Model 32140 at full capacity; Southeast Asia expansion customer-driven with major order near signing, mass production mid-2026. - **2024 Q4:** CBAT battery segment revenue up 2.7%, gross margin expands to 31.5%; capacity expansions underway for 32140 and 40135 cells targeting 7.6 GWh by end-2025; overseas factory planned for 2026 to mitigate tariffs; Hitrans drags consolidated results. - **2024 Q3:** CBAT Q3 battery revenue dipped to $33.5M due to Dalian shutdown; 9M revenue up 18% to $114M; gross margin 34.3%; Nanjing profitable; expanding capacity for 32140/40135; overseas factory early stage. - **2024 Q1:** CBAT Q1 2024: battery revenue $44.8M (+51.5% YoY), gross margin 41.2% (+30.3pp), net income $11.7M; guided FY24 battery net income $30.5-34.6M; expanding capacity 5-6 GWh by year-end; developing 40140/46140 cells; sodium-ion project seeking separate financing. - **2023 Q4:** CBAT Q4 battery revenue +30.9% YoY to $36.8M, gross margin 36% historic high, net income $6.6M; full-year revenue $133M (+40.4%); $107M order backlog plus $195M Viessmann orders; sodium ion mass production since Q2 2023; Nanjing Phase 2 (18 GWh) under construction; PE financing talks for sodium ion ## Theme arcs - **Battery gross margin** (deteriorating): Margins fell from historic 36% in 2023 Q4 to 31.5% in 2024 Q4 and 7.3% in 2025 Q4 as new lines ramped - **Demand backlog strength** (stable): Backlog remained robust across calls, with major client commitments from Viessmann, Anker, PowerOAK and Southeast Asia orders - **Capacity expansion execution** (deteriorating): Multiple expansions (Nanjing Phase 2, Dalian 40135) faced delays, capacity reductions and ramp‑up risks - **Overseas factory development** (new): First mentioned in 2024 Q4, with term sheet in 2025 Q3, still pending policy clarity - **Hitrans segment recovery** (improving): From loss‑making in 2024 Q4 to revenue up 59% in 2025 Q2 and profit improvement in 2025 Q3 - **Tariff and geopolitical risk** (deteriorating): Customers push overseas capacity to avoid tariffs; policy uncertainty cited repeatedly - **Revenue volatility from technology transition** (deteriorating): Q1 2025 revenue fell 41% YoY as Dalian shifted from 26650 to 40135, with gradual recovery expected ## Guidance path 2023 Q4:vague → 2024 Q1:maintained → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/CBAT`